I wouldn't have gone down the line of suicide - The MHRA will never see that Seroxat causes suicide or thoughts of suicide. They would always argue that it is the illness that could have caused the suicide. I disagree and urge Kent Woods to read the Glenmullen Report that was passed onto his Enforcement Officers after I sent it to the MHRA about two months ago.
The investigation into GSK by the MHRA Enforcement Team needs to be reveiwed impartially. The legal speak I heard on the audio recording didn't really address any outstanding issues. The Enforcement Team made no arrests so cannot name the suspects - in my opinion this was because of one thing... and one thing only. MUD STICKS
Now questions that I would have asked if I had been given the opportunity to attend the meeting.
Firstly, only one member who introduced themselves was a user or former user of Seroxat. One out of a total of the 7 who introduced themselves. The others were three members of the MHRA, one solicitor (Criminal Lawyer) who was drafted in by the MHRA to help with the GSK investigation.
Batting for the other side were, one Seroxat user, one campaigner and one solicitor.
If you want to hear patient stories about the struggles they have on this drug then sit down with patients who have taken and struggled with Seroxat. To restrict the opposition to only have a certain amount of ammunition is, in my mind, sticking two fingers up to the patient voice.
Anyway, I doubt very much if I or any other outspoken individuals will get our day with Kent Woods - until we do we shall just have to keep blogging.
Questions I would have raised would have been the following:
1. If the MHRA claim that they monitor SSRi's on a regular basis how come they never learned that these particular class of drugs are about as useful as a placebo in patients suffering with mild to moderate depression? It took a study from the University of Hull to disseminate these facts to the public. Do the MHRA regret that they never declared in public that SSRi treatment in patients suffering with mild to moderate depression is basically 'useless'? (If indeed that is their stance) - I will add that providing information on the MHRA website is NOT acceptable. In the words of Shelly Jofre 'Who reads the MHRA website?'
2. Does the yellow card ask whether or not the patient is suffering from mild, moderate or severe depression? If not, why?
3. Are patients reports followed up by the MHRA, if so, are patients with mild to moderate depression told by the MHRA that the SSRi they have been prescribed is about as useful as a placebo? If not, why?
4. Do the MHRA agree that there is a severe withdrawal problem in some patients tapering off Seroxat? By severe I mean so bad that the patient has to continue taking Seroxat because they find it impossible to stop and in doing so this brings on a series of horrific side effects.
5. Do the MHRA stand by Mary Anne Rhyne's (GSK) claim that side effects are moderate and last for about two weeks?
6. What study, if any, have the MHRA taken out regarding the tapering of Seroxat?
7. Is anyone at the MHRA prepared to partake in a controlled healthy volunteer study and take a course of Seroxat for a period of 3 months? This study would be accessible by the public so results could not be manipulated in any way. I would prefer healthy volunteers who didn't have a long history of depression and/or volunteers who didn't dabble in illegal substances.
8. What is the current method offered by the MHRA for tapering off Seroxat and what is this based on?
9. As far as the MHRA are aware, is Seroxat used to treat any other illness apart from the following:
Depression
Obsessive Compulsive Disorder (obsessions and compulsions)
Panic Disorder (panic attacks)
Social Anxiety Disorder (fear or avoidance of social situations)
Post Traumatic Stress Disorder
Generalised Anxiety Disorder
10. If the MHRA's stance is that there is no real problem with Seroxat withdrawal in adults and it is not as widespread as they think. Can they explain to the thousands of people who have suffered... and are still suffering and why they experience some, if not all, of the following:
Malaise (a vague feeling of bodily discomfort), pain. Cardiovascular: Hypertension, syncope (a sudden loss of strength, a temporary suspension of consciousness due to cerebral anemia), tachycardia (excessive rapidity in the action of the heart). Dermatological: Pruritus (Intense itching) Gastrointestinal: Nausea and vomiting. Metabolic and Nutritional: Weight gain, weight loss. Nervous System: Central Nervous System stimulation, concentration impaired, depression, emotional lability (emotional instability), vertigo (a hallucination of movement; a sensation as if the external world were revolving around the patient or as if he himself were revolving in space). Respiratory: Cough increased, rhinitis (inflammation of the mucus membrane of the nose). Infrequent were abnormality of accommodation (trouble seeing distances), conjunctivitis (inflammation of the inner eyelids), earache, keratoconjunctivitis (inflammation of both the inner eyelid and the inner covering of the eye), mydriasis (extreme enlargement of the pupil of the eye), photophobia (inability to tolerate light), retinal hemorrhage (bleeding from the eye), tinnitus (ringing or clicking in the ears), visual field defect (not having a normal field of vision); also observed were amblyopia (dimness of vision), anisocoria (having pupils of different size), blepharitis (inflammation of the eyelids), blurred vision, cataract (cloudy formation on the eye, often resulting in partial blindness), conjunctival edema (excessive fluid built up in eyelids), corneal ulcer (open sore on the eye covering), deafness, exophthalmos (abnormal protrusion of the eyeball), glaucoma (disease of the eyes resulting in gradual loss of sight), hyperacusis (abnormal hearing sensitivity), night blindness, parosmia (altering of the sense of smell), ptosis (drooping of the eyelid), taste loss. Infrequent were anaphylactoid reaction (allergic reaction), chills, flu syndrome, malaise (a vague feeling of bodily discomfort); also observed were adrenergic syndrome (one organ or body part mimicking the pain or distress of another body part), face edema (excessive fluid buildup in the face), neck rigidity, sepsis (a range of conditions which can run up to and include multiple organ failure and death). Allergic reaction, chills, face edema (abnormal amount of fluid in the facial tissue), infection, moniliasis (infection caused by Candida (yeast like fungi), neck pain, overdose. Cardiovascular: Bradycardia (abnormal slowness of the heartbeat), conduction abnormalities (abnormal transfer of sound waves, heat, nerve influences, or electricity), ECG abnormal, hypotension (lowered blood pressure), migraine, ventricular extrasystoles (a premature contraction of the heart). Dermatological: Acne, alopecia (absence of hair from the body where it is normally present), dry skin, ecchymosis (blood under the skin, usually looks or appears like a bruise), eczema (an inflammatory skin disease characterized by lesions varying greatly in character, at times watery discharge and the development of scales and crust), furunculosis (a number of painful nodules formed in the skin, caused by bacteria, which enter through the hair follicles or glands, its formation is favored by digestive derangement and local irritation), herpes simplex, urticaria (reaction of the skin to certain drugs, marked by the appearance of smooth, slightly elevated patches, which are redder or paler than the surrounding skin and often includes severe itching). Gastrointestinal: Bruxism (grinding of the teeth especially during sleep), buccal cavity disorders (cavity running from the cheeks to the lips), dysphagia (inflammation of the esophagus), eructation (the act of belching or casting up wind from the stomach), gastroentertitis (inflammation of the stomach or intestines), gastrointestinal flu, glossitis (inflammation of the tongue), increased salivation, liver function test abnormal, mouth ulceration, vomiting and diarrhea, rectal hemorrhage. Hematologic and Lymphatic: Anemia, leukopenia (reduction in the number of leukocytes in the blood), lymphadenopathy (disease of the lymphnodes), purpura (condition charactized by the presence of blood just under the skin, can appear any where over the body), WBC abnormality (white blood cell abnormality). Musculoskeletal: Arthralgia (pain in the joint), arthritis, traumatic fracture. Nervous System: Akinesia (the temporary paralysis of a muscle, can include intense pain), alcohol abuse, amnesia, ataxia (failure of muscular coordination or irregularity of muscle action), convulsion, depersonalization, hallucinations, hyperkinesia (abnormally increased mobility, abnormally increased motor function or activity), hypertonia (a condition of excessive tone, tension or activity, can include increased blood pressure), incoordination, lack of emotion, manic reaction, paranoid reaction, thinking abnormal. Respiratory: Asthma, bronchitis, dyspnea (difficult or labored breathing), epistaxis (hemorrhage from the nose), hyperventilation, pneumonia, respiratory flu, sinusitis. Special Senses: Abnormality of accommodation, conjunctivitis, ear pain, eye pain, mydriasis (extreme or morbid dilation of the pupil), otitis media (inflammation of the ear which may be marked by pain, fever, abnormalities of hearing, deafness, tinnitus, and vertigo), tinnitus (a noise in the ear, as ringing, buzzing, roaring clicking etc). Urogenital: Abortion*, amenorrhea* (absence or abnormal stoppage of menses), breast pain*, cystitis (inflammation of the urinary bladder), dysmenorrhea* (painful menstruation), dysuria (painful or difficult urination), menorrhagia* (excessive uterine bleeding occurring at regular intervals), nocturia (excessive urination at night), polyuria (the passage of a large volume of urine in a given period), urinary incontinence, urinary retention, urinary tract infection, urinary urgency, vaginitis* (inflammation of the vagina).
* Gender specific
Side-effects taken from
http://www.psychdrugtruth.com/paxil.htm
Regards
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
By Bob Fiddaman
ISBN: 978-1-84991-120-7
CHIPMUNKA PUBLISHING
AVAILABLE FOR DOWNLOAD HERE
PAPERBACK COMING SOON
2 comments: